<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Testicular sex cord stromal tumors</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Testicular sex cord stromal tumors</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Testicular sex cord stromal tumors</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mary-Ellen Taplin, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Timothy D Gilligan, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 25, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Sex cord stromal tumors (SCSTs) comprise approximately 5 percent of all testicular tumors, while the remainder are of germ cell origin [<a href="#rid1">1-3</a>]. SCSTs, which arise from the supporting tissues of the testis, include Leydig, Sertoli, and granulosa cell tumors, as well as tumors in the fibroma-thecoma family of tumors, and mixed and other SCST subtypes  (<a class="graphic graphic_table graphicRef115023" href="/z/d/graphic/115023.html" rel="external">table 1</a>) [<a href="#rid4">4-8</a>].</p><p>The clinical presentation and management of SCSTs are discussed here. The following topics are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>Anatomy and pathology of SCSTs (see  <a class="medical medical_review" href="/z/d/html/2949.html" rel="external">"Anatomy and pathology of testicular tumors", section on 'Sex cord-stromal tumors'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinical manifestations, diagnosis, and staging of testicular germ cell tumors (see  <a class="medical medical_review" href="/z/d/html/2980.html" rel="external">"Clinical manifestations, diagnosis, and staging of testicular germ cell tumors"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment approach to testicular germ cell tumors (see  <a class="medical medical_review" href="/z/d/html/2981.html" rel="external">"Initial risk-stratified treatment for advanced testicular germ cell tumors"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment approach to ovarian SCSTs (see  <a class="medical medical_review" href="/z/d/html/126385.html" rel="external">"Sex cord-stromal tumors of the ovary: Management in adults"</a>)</p><p></p><p class="headingAnchor" id="H2487199035"><span class="h1">CLASSIFICATION AND EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>According to the World Health Organization (WHO), testicular non-germ cell tumors are classified as follows  (<a class="graphic graphic_table graphicRef115023" href="/z/d/graphic/115023.html" rel="external">table 1</a>) [<a href="#rid8">8</a>]:</p><p class="headingAnchor" id="H1432240857"><span class="h2">Leydig cell tumors</span><span class="headingEndMark"> — </span>Leydig cell tumors are the most common testicular SCSTs and account for 1 to 2 percent of all testicular tumors [<a href="#rid2">2</a>]. In a series of approximately 79,000 cases of testicular cancer in the National Cancer Database, 250 were malignant Leydig tumors (0.3 percent) [<a href="#rid9">9</a>]. The pathology of these tumors is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2949.html" rel="external">"Anatomy and pathology of testicular tumors", section on 'Leydig cell tumors'</a>.)</p><p>Leydig cell tumors can present at any age, with peak presentations in children between the ages of 5 and 10 years and in adults between the ages of 30 and 35 years [<a href="#rid2">2</a>]. These tumors are most commonly diagnosed in adults [<a href="#rid4">4,10</a>].</p><p class="headingAnchor" id="H1033459902"><span class="h2">Sertoli cell tumors</span><span class="headingEndMark"> — </span>Sertoli cell tumors (SCT) are classified as malignant Sertoli cell tumor (not otherwise specified [NOS]) and large cell calcifying Sertoli cell tumor (LCCSCT). Sclerosing SCT is part of the spectrum of SCT NOS [<a href="#rid11">11</a>]. Sertoli cell tumors are the second most common type of testicular SCST, after Leydig cell tumors, and account for 0.1 percent of testicular tumors in an analysis from the National Cancer Database [<a href="#rid2">2,9</a>]. (See  <a class="medical medical_review" href="/z/d/html/2949.html" rel="external">"Anatomy and pathology of testicular tumors", section on 'Sertoli cell tumors'</a>.)</p><p>Sertoli cell tumors can present at any age, with a reported mean of 45 years [<a href="#rid5">5</a>]. However, patients with the large cell calcifying variant tend to be younger, with an average age at diagnosis of 21 years [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H1457295671"><span class="h2">Granulosa cell tumors</span><span class="headingEndMark"> — </span>Granulosa cell tumors are rare neoplasms that are similar to their ovarian counterparts. They are divided into adult and juvenile types. (See  <a class="medical medical_review" href="/z/d/html/2949.html" rel="external">"Anatomy and pathology of testicular tumors", section on 'Granulosa cell tumors'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adult type</strong> – The adult type of granulosa cell tumor is very rare in the testis [<a href="#rid13">13</a>]. The average age at presentation is 44 years [<a href="#rid2">2,14,15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Juvenile type</strong> – The juvenile type of granulosa cell tumor is the most common testicular tumor of infancy and is only rarely seen in adults [<a href="#rid16">16</a>]. These tumors are most commonly seen in infants less than six months old [<a href="#rid3">3</a>]. These tumors appear to be uniformly benign.</p><p></p><p class="headingAnchor" id="H1690647477"><span class="h2">Other tumor types</span><span class="headingEndMark"> — </span>Other stromal tumors arising in the testis include: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>The fibroma-thecoma family of tumors</strong> –<strong> </strong>Testicular fibromas are very rare with approximately 50 total reported cases [<a href="#rid17">17</a>]. Testicular fibromas are derived from either the gonadal stroma or tunica albuginea. While they resemble ovarian fibromas, these tumors are much rarer. (See  <a class="medical medical_review" href="/z/d/html/2949.html" rel="external">"Anatomy and pathology of testicular tumors", section on 'Fibroma thecoma family of tumors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mixed and other sex cord stromal tumors</strong> – These tumors contain either a mixture of sex cord stromal elements or cells with no specific differentiation. These tumors comprise about five percent of SCSTs. Approximately 50 percent of these tumors occur in children, although they can present at any age. (See  <a class="medical medical_review" href="/z/d/html/2949.html" rel="external">"Anatomy and pathology of testicular tumors", section on 'Mixed and other sex cord-stromal tumors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gonadoblastoma</strong> – Gonadoblastoma is composed of neoplastic germ cells and sex cord stromal cells. It is a precursor of invasive tumors such as dysgerminoma/seminoma. Gonadoblastomas usually occur with disorders of sex development before age 20 and involve the bilateral testes [<a href="#rid11">11</a>]. (See  <a class="medical medical_review" href="/z/d/html/2949.html" rel="external">"Anatomy and pathology of testicular tumors", section on 'Gonadoblastoma'</a> and <a class="local">'Additional diagnostic evaluations'</a> below.)</p><p></p><p class="headingAnchor" id="H1521275018"><span class="h1">RISK FACTORS</span><span class="headingEndMark"> — </span>There are no known risk factors for testicular SCSTs, although some may be associated with certain genetic conditions. (See <a class="local">'Additional diagnostic evaluations'</a> below.)</p><p class="headingAnchor" id="H526921536"><span class="h2">Is cryptorchidism a risk factor?</span><span class="headingEndMark"> — </span>Unlike testicular germ cell tumors, there has been no definitive association with cryptorchidism or testicular dysgenesis (with the exception of gonadoblastoma), although such associations cannot be excluded [<a href="#rid10">10,18</a>]. Cryptorchidism and testicular germ cell tumors are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2980.html" rel="external">"Clinical manifestations, diagnosis, and staging of testicular germ cell tumors", section on 'Cryptorchidism'</a> and  <a class="medical medical_review" href="/z/d/html/2997.html" rel="external">"Epidemiology and risk factors for testicular cancer", section on 'Cryptorchidism'</a> and  <a class="medical medical_review" href="/z/d/html/2955.html" rel="external">"Treatment-related toxicity in testicular germ cell tumors", section on 'Gonadal effects'</a>.)</p><p class="headingAnchor" id="H1538932869"><span class="h1">CLINICAL PRESENTATION</span></p><p class="headingAnchor" id="H3235175214"><span class="h2">Symptoms</span><span class="headingEndMark"> — </span>The diagnosis of testicular SCST should be suspected in young adults and prepubescent males presenting with testicular abnormalities and/or other specific endocrinologic manifestations, such as gynecomastia [<a href="#rid3">3,4,19</a>].</p><p class="headingAnchor" id="H668981673"><span class="h3">Testicular mass</span><span class="headingEndMark"> — </span>The most common clinical presentation in patients with testicular SCST is an asymmetric testicular mass. While a majority of masses are painless, some may present with dull discomfort, scrotal heaviness, or swelling [<a href="#rid3">3,20</a>]. Acute testicular pain is rare and may indicate bleeding within the tumor or concomitant epididymitis [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H2268718187"><span class="h3">Endocrine manifestations</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adults</strong> – In adults, endocrine manifestations are found in 20 to 30 percent of patients with SCST and may precede development of a testicular mass [<a href="#rid3">3,21</a>]. Patients with Leydig cells tumors may present with either virilizing or feminizing symptoms, as Leydig cells are capable of producing both androgens and estrogen [<a href="#rid10">10</a>]. By contrast, patients with Sertoli cell tumors may present with signs of feminization (due to hyperestrogenism) in 20 to 30 percent of cases, but virilization is rarely seen. Further details on the histologic subtypes of testicular SCSTs are found above. (See <a class="local">'Classification and epidemiology'</a> above.)</p><p></p><p class="bulletIndent1">The most common endocrinologic symptom is gynecomastia, which occurs in 20 to 30 percent of patients with Leydig cell tumors [<a href="#rid22">22</a>]; 26 to 33 percent of those with Sertoli cell tumors [<a href="#rid23">23</a>]; and 20 to 50 percent of those with adult type granulosa cell tumors [<a href="#rid2">2,14,15</a>]. Gynecomastia is typically caused by excess estrogen production from the SCST but may also result from excess <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> from the tumor that is converted to estrogen via aromatization in peripheral tissues [<a href="#rid24">24</a>]. (See  <a class="medical medical_review" href="/z/d/html/7476.html" rel="external">"Clinical features, diagnosis, and evaluation of gynecomastia in adults"</a>.)</p><p></p><p class="bulletIndent1">Other common endocrinologic symptoms in adults include impotence, loss of libido, erectile dysfunction, and infertility [<a href="#rid1">1,10,20,22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Children</strong> – Children with testicular SCSTs commonly present with precocious puberty [<a href="#rid25">25</a>]. In those with Leydig cell tumors, precocious puberty is typically noted between the ages of 6 and 10 years [<a href="#rid1">1</a>]. In boys with precocious puberty, Leydig cell tumor should be considered if asymmetric testicular enlargement is also present. Signs and symptoms of precocious puberty are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5812.html" rel="external">"Definition, etiology, and evaluation of precocious puberty", section on 'Classification'</a>.)</p><p></p><p class="bulletIndent1">In contrast to older children, infants with juvenile granulosa cell tumors lack hormonal symptoms. These patients more typically present with sex chromosome abnormalities, ambiguous genitalia, and ipsilateral cryptorchidism [<a href="#rid26">26</a>].</p><p></p><p class="headingAnchor" id="H1053581506"><span class="h3">Systemic symptoms</span><span class="headingEndMark"> — </span>Systemic symptoms are less common as approximately 10 to 20 percent of patients present with metastatic disease at initial diagnosis [<a href="#rid3">3</a>]. The most common sites of metastatic disease are the retroperitoneal lymph nodes (70 percent). Less common sites of disease include the liver (45 percent), lungs (40 percent), and bones (25 percent) [<a href="#rid3">3,4,27,28</a>].</p><p>Patients with symptomatic involvement of these sites may present with constitutional symptoms (eg, weight loss), pulmonary symptoms (eg, cough, shortness of breath, chest pain), abdominal pain, or bony discomfort. Patients with retroperitoneal involvement are typically asymptomatic. Unlike testicular germ cell tumors, neurologic symptoms due to brain metastases are extremely rare [<a href="#rid29">29</a>].</p><p>The clinical presentation for testicular germ cell tumors is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2980.html" rel="external">"Clinical manifestations, diagnosis, and staging of testicular germ cell tumors", section on 'Clinical manifestations'</a>.)</p><p class="headingAnchor" id="H1100301709"><span class="h2">Age of presentation</span><span class="headingEndMark"> — </span>SCSTs most commonly present in young adults and prepubescent males. In general, there is a wide age range for adults with SCSTs, ranging between 14 and 87 years [<a href="#rid30">30,31</a>]. The age of presentation is associated with each particular histologic subtype and is discussed separately. (See <a class="local">'Classification and epidemiology'</a> above.)</p><p class="headingAnchor" id="H3282893980"><span class="h2">Physical exam</span><span class="headingEndMark"> — </span>In patients with suspected testicular SCST, physical exam should include a testicular exam, and the approach is similar to that of patients with suspected testicular germ cell tumors. (See  <a class="medical medical_review" href="/z/d/html/2980.html" rel="external">"Clinical manifestations, diagnosis, and staging of testicular germ cell tumors", section on 'Testicular examination'</a>.)</p><p>The most common physical exam finding in young adults and prepubescent males is a palpable, asymmetric testicular mass. Testicular masses may also be discovered incidentally on routine physical examination or during scrotal ultrasound evaluation for endocrine symptoms and/or excess sex hormone production [<a href="#rid4">4,19</a>].</p><p>Prepubescent males should also be evaluated for signs of precocious puberty, which may include testicular and penile enlargement, pubic and/or axillary hair, and apocrine odor. Other signs include increased linear growth for age and advanced bone age. In particular, Leydig cell tumors should be suspected in patients with precocious puberty if asymmetric testicular enlargement is also present and continues to increase on clinical follow-up. (See <a class="local">'Additional diagnostic evaluations'</a> below.)</p><p>By contrast, exam findings on infants with juvenile granulosa cell tumors include ambiguous genitalia and ipsilateral cryptorchidism [<a href="#rid26">26</a>].</p><p>The chest should be examined for gynecomastia, another common physical exam finding. It is important to obtain a baseline assessment of gynecomastia at diagnosis, which can be clinically monitored to indirectly assess treatment response and possible disease recurrence. (See <a class="local">'Surveillance'</a> below.)</p><p>Gynecomastia may be the initial presenting symptom of a testicular SCST and, in some cases, even precede the development of a testicular mass or other endocrinologic abnormalities [<a href="#rid21">21</a>]. Therefore, diagnostic evaluation for a testicular mass should still be obtained in patients with gynecomastia and a normal manual testicular exam. (See <a class="local">'Diagnostic evaluation'</a> below.)</p><p>The lungs should be auscultated for potential lung/thoracic involvement and the abdomen palpated for potential liver involvement. Although most bony involvement may be asymptomatic, any areas of bony discomfort should be carefully examined for discrete tenderness to palpation or fractures. (See  <a class="medical medical_review" href="/z/d/html/91912.html" rel="external">"Epidemiology, clinical presentation, and diagnosis of bone metastasis in adults"</a>.)</p><p class="headingAnchor" id="H3350435808"><span class="h1">DIAGNOSTIC EVALUATION</span><span class="headingEndMark"> — </span>An SCST should be suspected in patients with a testicular mass and endocrinologic abnormalities (ie, gynecomastia). (See <a class="local">'Clinical presentation'</a> above.)</p><p>The initial diagnostic evaluation of a patient with a suspected SCST is discussed below.</p><p class="headingAnchor" id="H1237892939"><span class="h2">Scrotal ultrasound</span><span class="headingEndMark"> — </span>Scrotal ultrasound is the diagnostic imaging tool of preference, as it has a high sensitivity for diagnosing testicular tumors (98 to 100 percent) [<a href="#rid3">3</a>]. Scrotal ultrasound can also be used to distinguish testicular SCST from other non-malignant diagnoses such as epididymitis or hydrocele. However, ultrasound findings for certain testicular SCST and germ cell tumors may be similar, and pathology is needed to distinguish between the two possible diagnoses. (See <a class="local">'Diagnosis'</a> below.)</p><p>For example, Leydig cell tumors typically appear as hypoechoic and hypervascular lesions on ultrasound [<a href="#rid3">3</a>]. Large cell calcifying Sertoli cell tumors have a classic presentation on ultrasound, including dense areas of calcification within the involved testis [<a href="#rid32">32</a>]. By contrast, Sertoli cell tumors and testicular germ cell tumors (such as seminomas) may both be hypoechoic with peripheral vascularity and thus difficult to distinguish from each other on ultrasound alone without surgical pathology [<a href="#rid33">33</a>]. The specific ultrasound findings for patients with testicular germ cell tumors are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2980.html" rel="external">"Clinical manifestations, diagnosis, and staging of testicular germ cell tumors", section on 'Scrotal ultrasound'</a>.)</p><p class="headingAnchor" id="H1838809497"><span class="h2">Tumor markers and hormonal markers</span><span class="headingEndMark"> — </span>In patients with a suspected testicular SCST, we evaluate for both tumor markers and hormonal markers [<a href="#rid3">3</a>]. For tumor markers, we check lactate dehydrogenase (LDH), alpha-fetoprotein (AFP), and beta-human chorionic gonadotropin (B-hCG). For hormonal markers, we check <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a>, luteinizing hormone (LH), and follicle-stimulating hormone (FSH). If tumor markers are not detected, or if patients have signs of feminization, we also check estrogen, estradiol, progesterone, and cortisol.</p><p>Normal levels of LDH, AFP, and hCG may indicate the diagnosis of a testicular SCST, which does not produce these particular tumor markers [<a href="#rid3">3</a>] but cannot distinguish between testicular SCSTs and other germ cell tumors (which can also lack these tumor markers). By contrast, elevated levels of these tumor markers could indicate the presence of a testicular germ cell tumor as an alternative diagnosis. (See  <a class="medical medical_review" href="/z/d/html/2980.html" rel="external">"Clinical manifestations, diagnosis, and staging of testicular germ cell tumors", section on 'Serum tumor markers'</a>.)</p><p>Similarly, hormonal markers are more commonly elevated in patients with testicular SCST compared with patients with germ cell tumors, who typically have normal serum levels of LH, FSH, <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a>, and estradiol [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H2530442811"><span class="h2">Additional diagnostic evaluations</span><span class="headingEndMark"> — </span>In patients with a suspected diagnosis of testicular SCST, additional diagnostic evaluations are suggested for the following specific findings:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Precocious puberty</strong> – The diagnosis of testicular SCSTs should be suspected in prepubescent boys with precocious puberty and testicular asymmetry. Even if a distinct mass cannot be palpated and is not detectable by ultrasonography, the larger testis should be assessed surgically if it enlarges during follow-up. (See  <a class="medical medical_review" href="/z/d/html/5812.html" rel="external">"Definition, etiology, and evaluation of precocious puberty", section on 'Males'</a> and <a class="local">'Diagnosis'</a> below.)</p><p></p><p class="bulletIndent1">These patients should also be assessed for congenital adrenal hyperplasia, which can also present in children with symptoms of virilizing precocious puberty or ambiguous genitalia and can be associated with hyperplastic testicular nodules. (See  <a class="medical medical_review" href="/z/d/html/145.html" rel="external">"Clinical manifestations and diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic conditions</strong> – Testicular SCSTs can, in rare circumstances, be associated with certain genetic conditions. For example, Leydig cell tumors can be associated with certain genetics conditions such as Klinefelter syndrome, hereditary leiomyomatosis, and hereditary renal cell cancer syndromes [<a href="#rid2">2,34,35</a>]. Sertoli cell testicular tumors have been associated with two inherited disorders, Peutz-Jeghers syndrome and Carney complex [<a href="#rid36">36,37</a>]. Gonadoblastomas can be associated with male pseudohermaphroditism with presenting features of cryptorchidism, hypospadias, and gynecomastia.</p><p></p><p class="bulletIndent1">Males with signs or symptoms of such conditions should seek clinical evaluation and appropriate genetic counseling. As examples:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Unexplained infertility should prompt an evaluation for Klinefelter syndrome, which is associated with Leydig cell tumors. The diagnosis of Klinefelter syndrome is often made in adulthood due to the variability of phenotype severity and the failure of many clinicians to recognize its clinical features. (See  <a class="medical medical_review" href="/z/d/html/13921.html" rel="external">"Clinical features, diagnosis, and management of Klinefelter syndrome"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Multiple skin leiomyomata and/or renal masses should prompt an evaluation for hereditary leiomyomatosis and renal cell cancer syndrome (HLRCC), which has also been associated with Leydig cell tumors [<a href="#rid34">34</a>]. (See  <a class="medical medical_review" href="/z/d/html/2948.html" rel="external">"Hereditary kidney cancer syndromes", section on 'Hereditary leiomyomatosis and renal cell cancer syndrome'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Multiple hamartomatous polyps in the gastrointestinal tract, mucocutaneous pigmentation, and a history of certain gastrointestinal malignancies should prompt an evaluation for Peutz-Jeghers syndrome, which is associated with Sertoli cell tumors. (See  <a class="medical medical_review" href="/z/d/html/2533.html" rel="external">"Peutz-Jeghers syndrome: Clinical manifestations, diagnosis, and management"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Distinctive pigmented lesions of the skin and mucosal surfaces, cardiac and noncardiac myxomatous tumors, and multiple endocrine tumors should prompt an evaluation for Carney complex, which is also associated with Sertoli cell tumors. (See  <a class="medical medical_review" href="/z/d/html/100662.html" rel="external">"Carney complex", section on 'Diagnosis'</a>.)</p><p></p><p class="headingAnchor" id="H1444802976"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis for patients with similar signs and symptoms to those with SCSTs includes both malignant and benign etiologies.</p><p>Malignant etiologies include testicular germ cell tumors and tumors of other cell types presenting in the testes such as lymphoma, carcinoid tumors, and metastatic carcinoma. (See  <a class="medical medical_review" href="/z/d/html/2949.html" rel="external">"Anatomy and pathology of testicular tumors"</a>.)</p><p>Benign etiologies include epididymitis, epididymo-orchitis, and testicular torsion [<a href="#rid3">3</a>]. Less commonly, this presentation can be associated with hernias, hematomas, hydrocele, spermatocele, varicocele, or hematocele. (See  <a class="medical medical_review" href="/z/d/html/6873.html" rel="external">"Acute scrotal pain in adults"</a> and  <a class="medical medical_review" href="/z/d/html/6446.html" rel="external">"Causes of scrotal pain in children and adolescents"</a>.)</p><p class="headingAnchor" id="H2526434205"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis and histologic classification of an SCST is made on pathologic evaluation upon surgical resection of the testicular tumor.</p><p class="headingAnchor" id="H4053483292"><span class="h2">Radical orchiectomy</span><span class="headingEndMark"> — </span>All patients undergo initial surgical treatment with inguinal orchiectomy [<a href="#rid38">38,39</a>]. Surgical resection establishes the histopathologic diagnosis, treats the primary tumor, and predicts risk for metastatic disease (based on the pathologic findings at orchiectomy). (See <a class="local">'Stage IIA or high-risk features on orchiectomy'</a> below.)</p><p>Radical resection remains the procedure of choice over partial orchiectomy [<a href="#rid38">38</a>]. Although retrospective observational data suggest that partial orchiectomy results in similar disease-free survival (DFS) compared with radical orchiectomy [<a href="#rid39">39</a>], there are limited prospective data to inform the decision between the two procedures. As an example, in one observational study of 56 patients with Leydig cell tumors, the local recurrence rate for partial orchiectomy was 10 versus 0 percent for radical orchiectomy. DFS was similar between the two treatment arms [<a href="#rid39">39</a>].</p><p class="headingAnchor" id="H3631259543"><span class="h1">EVALUATION OF CONFIRMED DISEASE</span></p><p class="headingAnchor" id="H3616237652"><span class="h2">Staging imaging</span><span class="headingEndMark"> — </span>For patients with histologically confirmed Leydig, Sertoli, or granulosa cell tumors on orchiectomy specimens, we suggest staging for evidence of metastatic disease using computed tomography (CT) of the chest, abdomen, and pelvis. (See <a class="local">'Radical orchiectomy'</a> above.)</p><p>The role of positron emission tomography-CT (PET-CT) scans for staging of these tumors has not been defined. The presence of symptoms should determine whether other tests (eg, bone scan, neuroimaging) are indicated to evaluate for distant metastatic disease.</p><p>Patients with testicular SCST are staged using pathology from orchiectomy specimens and from systemic imaging, using the American Joint Committee on Cancer (AJCC) eighth edition staging system for testicular germ cell tumors  (<a class="graphic graphic_table graphicRef110731 graphicRef110732" href="/z/d/graphic/110731.html" rel="external">table 2A-B</a>) [<a href="#rid40">40</a>]. Children are staged using the Children's Oncology Group staging system  (<a class="graphic graphic_table graphicRef128141" href="/z/d/graphic/128141.html" rel="external">table 3</a>), which is also applicable to those with both germ cell and SCST histologies.</p><p class="headingAnchor" id="H3881947959"><span class="h2">Assessment of pituitary/gonadal axis</span><span class="headingEndMark"> — </span>In patients with histologically confirmed Leydig, Sertoli, or granulosa cell tumors, assessment of the pituitary/gonadal axis is recommended regardless of whether patients have localized or metastatic disease. This evaluation includes measurement of luteinizing hormone (LH), follicle-stimulating hormone (FSH), <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a>, progesterone, estrogen, estradiol, and cortisol [<a href="#rid5">5</a>]. These labs may have been assessed prior to histologic confirmation, based on clinical suspicion for the diagnosis of testicular SCST. If any of these hormones were elevated, they may be serially evaluated as a marker of response to therapy, such as orchiectomy. (See <a class="local">'Tumor markers and hormonal markers'</a> above.)</p><p>The incidence of hypogonadism after orchiectomy appears to be higher in males with SCSTs than in those with germ cell tumors (42 versus 5 to 13 percent) [<a href="#rid4">4,41</a>]. Thus, males with SCSTs are more likely to need <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> replacement following surgery [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/z/d/html/7461.html" rel="external">"Testosterone treatment of male hypogonadism"</a>.)</p><p class="headingAnchor" id="H7"><span class="h1">MANAGEMENT AFTER ORCHIECTOMY</span></p><p class="headingAnchor" id="H1216077601"><span class="h2">Localized disease</span><span class="headingEndMark"> — </span>For patients with localized (stage I or II) disease, we suggest the approach outlined in the sections below.</p><p class="headingAnchor" id="H1018586332"><span class="h3">Stage I disease</span><span class="headingEndMark"> — </span>For patients with stage I disease  (<a class="graphic graphic_table graphicRef110731 graphicRef110732" href="/z/d/graphic/110731.html" rel="external">table 2A-B</a>) treated curatively with orchiectomy and without high-risk pathologic features, we suggest observation rather than further interventions, as these patients have a favorable prognosis. The approach to patients with high-risk pathologic features on orchiectomy is discussed below. (See <a class="local">'Stage IIA or high-risk features on orchiectomy'</a> below.)</p><p>The good prognosis for patients with clinical stage I disease is also supported by two single-institution retrospective series. In one report, 38 males were successfully managed with excision of the primary tumor alone [<a href="#rid42">42</a>]. At a median follow-up of seven years, none had developed metastatic disease. In another series of 48 males with short-term follow-up, the conclusion was that patients with one or no high-risk features can be safely observed without retroperitoneal lymph node dissection (RPLND) [<a href="#rid43">43,44</a>].</p><p class="headingAnchor" id="H2451495915"><span class="h3">Stage IIA or high-risk features on orchiectomy</span><span class="headingEndMark"> — </span>For patients with clinical stage IIA disease  (<a class="graphic graphic_table graphicRef110731 graphicRef110732" href="/z/d/graphic/110731.html" rel="external">table 2A-B</a>) or those with two or more high-risk features on orchiectomy, we suggest early RPLND rather than observation. These risk factors can predict the risk for occult metastatic disease at the time of orchiectomy [<a href="#rid45">45</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Tumor &gt;5 cm</p><p class="bulletIndent1"><span class="glyph">●</span>&gt;3 mitoses per high-powered field</p><p class="bulletIndent1"><span class="glyph">●</span>Positive margins</p><p class="bulletIndent1"><span class="glyph">●</span>Rete testis invasion</p><p class="bulletIndent1"><span class="glyph">●</span>Lymphovascular invasion (LVI)</p><p class="bulletIndent1"><span class="glyph">●</span>Cellular atypia</p><p class="bulletIndent1"><span class="glyph">●</span>Necrosis</p><p></p><p>Patients with a tumor demonstrating two or more risk factors had a five-year occult metastatic disease-free survival (DFS) of 48 percent. Patients with tumors demonstrating fewer than two risk factors have a five-year occult metastatic DFS of 98 percent [<a href="#rid45">45</a>]. In another observational study of 17 patients with testicular SCST treated with RPLND, there were no recurrences in five patients with stage I disease and at least two risk factors [<a href="#rid46">46</a>]. These risk projections provide a guide to features of metastatic potential, although they may be limited due to the retrospective nature and small size of the published series as well as the absence of central pathology review.</p><p>Patients at high risk for metastases based on this risk stratification who decline RPLND may be offered more frequent surveillance imaging. There are no specific guidelines for such surveillance imaging in patients with testicular SCST. One reasonable approach is to follow a surveillance schedule similar to those with nonseminoma germ cell tumors of comparable stage, who have undergone a similar treatment approach. If advanced disease is detected, RPLND and/or metastasectomy could be offered at that time. (See  <a class="medical medical_review" href="/z/d/html/2956.html" rel="external">"Posttreatment follow-up for testicular germ cell tumors", section on 'NSGCT'</a> and <a class="local">'Advanced or metastatic disease'</a> below.)</p><p class="headingAnchor" id="H3206123842"><span class="h2">Advanced or metastatic disease</span><span class="headingEndMark"> — </span>Patients with advanced or metastatic disease are typically treated with surgical resection of all sites of disease, as systemic chemotherapy and radiation have limited efficacy.</p><p class="headingAnchor" id="H3957963946"><span class="h3">Surgical resection of all metastatic sites</span><span class="headingEndMark"> — </span>All patients with suspected metastatic disease should undergo radical orchiectomy, similar to those with localized disease. Upon confirmation of metastatic disease on postsurgical imaging, we suggest surgical resection of all known sites of disease whenever possible. The most common procedures include RPLND and surgical metastasectomy of the lungs and liver. Such procedures typically occur separately from orchiectomy, which is required for initial histologic diagnosis [<a href="#rid3">3</a>]. (See <a class="local">'Radical orchiectomy'</a> above.)</p><p>RPLND has been used both as treatment in patients with established nodal disease on clinical imaging and as a staging procedure to resect microscopic disease [<a href="#rid5">5,43,45,47</a>]. In a large single-institution series, 17 patients with SCSTs underwent RPLND [<a href="#rid47">47</a>]. Among the nine with clinical stage I disease, retroperitoneal disease was not identified in any case, and all remained free of disease from 9 to 135 months after surgery. In the eight patients with clinical stage II or III disease, six died at 9 to 69 months after surgery, one was alive with disease at 13 months, and one was disease free at eight months.</p><p>In patients with limited metastatic disease to sites other than the retroperitoneal lymph nodes, metastasectomy is offered because the response to chemotherapy and radiotherapy is generally poor [<a href="#rid18">18,47-49</a>]. In one observational study of eight patients with metastatic disease treated with aggressive surgery including RPLND and metastasectomy, median overall survival was 1.2 years [<a href="#rid46">46,47</a>]. For those who do not pursue or delay surgery, survival is typically less than one year.</p><p class="headingAnchor" id="H2460449847"><span class="h3">Is there a role for chemotherapy or radiation?</span><span class="headingEndMark"> — </span>Systemic chemotherapy or radiation therapy (RT) have a limited role in patients with unresectable metastatic disease, as these treatments have low response rates [<a href="#rid50">50</a>]. We typically reserve these therapies for palliation in those with widespread unresectable disease. Patients should be referred for clinical trials where available.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cisplatin-based regimens for testicular cancer</strong> – Active testicular germ cell regimens such as BEP (<a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">bleomycin</a>, <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a>, <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>) or VIP (<a class="drug drug_general" data-topicid="10044" href="/z/d/drug information/10044.html" rel="external">vinblastine</a>, <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">ifosfamide</a>, cisplatin) have been relatively ineffective, with only transient responses [<a href="#rid4">4,47,51</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">Mitotane</a> – Leydig cell tumors and adrenocortical cancers have common histologic and biochemical features. Case reports of mitotane, an agent used in adrenocortical cancer, suggest low palliative response rates [<a href="#rid4">4,52,53</a>]. (See  <a class="medical medical_review" href="/z/d/html/165.html" rel="external">"Treatment of adrenocortical carcinoma", section on 'Mitotane monotherapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other systemic agents</strong> – Data are limited for the utility of other systemic agents, such as other chemotherapy regimens (eg, taxanes, <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a>), antiangiogenic agents, tyrosine kinase inhibitors, and checkpoint inhibitor immunotherapy [<a href="#rid54">54</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Radiation therapy (RT)</strong> – RT has generally been unsuccessful in the treatment of metastatic testicular SCSTs with limited response rates [<a href="#rid55">55,56</a>]. In select patients with spinal cord compression from bony metastases treated with initial surgery, postoperative radiation may be offered to palliate symptoms and/or attenuate the potential for recurrent tumor growth at the site of surgical decompression [<a href="#rid57">57</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical trials</strong> – Given the rarity of these tumors and lack of effective therapies for metastatic SCSTs, we suggest referral to a tertiary care center and evaluation for clinical trials where available. Tumor gene profiling to assess for actionable targets is also appropriate, in the context of detecting actionable mutations for such trials, although data are limited for the identification of therapeutic targets. As an example, in one report of tumor sequencing of primary and metastatic sites of testicular SCSTs, targetable genomic alterations were uncommon [<a href="#rid58">58</a>]. However, several potential molecular alterations could be targeted on clinical trials:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cell cycle inhibitors (cyclin-dependent kinase 4 [CDK4])</p><p class="bulletIndent2"><span class="glyph">•</span>Mechanistic target of rapamycin (mTOR) </p><p class="bulletIndent2"><span class="glyph">•</span>Moesin-ezrin-radixin like (MERLIN) tumor suppressor (NF2)</p><p class="bulletIndent2"><span class="glyph">•</span>Phosphatase and tensin homolog (PTEN) </p><p class="bulletIndent2"><span class="glyph">•</span>Hedgehog inhibitors (protein patched homolog 1 (PTCH1)</p><p class="bulletIndent2"><span class="glyph">•</span>Poly(ADP-ribose)-polymerase (PARP) inhibitors (breast cancer type 1 [BRCA1]-associated protein 1 [BAP1])</p><p></p><p class="bulletIndent1">Of note, there were no microsatellite instability (MSI)-high tumors, suggesting that these tumors may not be responsive to checkpoint inhibitor immunotherapy and that such therapy should be evaluated in the context of a clinical trial. (See  <a class="medical medical_review" href="/z/d/html/120646.html" rel="external">"Tissue-agnostic cancer therapy: DNA mismatch repair deficiency, tumor mutational burden, and response to immune checkpoint blockade in solid tumors"</a>.)</p><p></p><p class="headingAnchor" id="H506484734"><span class="h1">PROGNOSIS</span></p><p class="headingAnchor" id="H53755341"><span class="h2">Localized disease</span><span class="headingEndMark"> — </span>Patients with localized disease  (<a class="graphic graphic_table graphicRef110731 graphicRef110732" href="/z/d/graphic/110731.html" rel="external">table 2A-B</a>) have an overall favorable prognosis, and treatment intent is typically curative. Five-year overall survival rates range between 91 percent for those with Leydig cell tumors and 77 percent for those with Sertoli cell tumors [<a href="#rid9">9,42</a>].</p><p class="headingAnchor" id="H2209282226"><span class="h2">Advanced or metastatic disease</span><span class="headingEndMark"> — </span>Although most testicular SCSTs are benign, the prognosis is poor for patients with advanced or metastatic SCSTs (ie, those with disease that has metastasized to the retroperitoneal lymph nodes or distant organs). Approximately 10 to 20 percent of patients with SCSTs develop distant metastases and ultimately die from their disease. Although prolonged survival has been reported, the median survival is between one and two years, and two-thirds of patients die within two years of developing metastases [<a href="#rid4">4,10,59</a>].</p><p class="headingAnchor" id="H2380507834"><span class="h1">SURVEILLANCE</span><span class="headingEndMark"> — </span>In patients treated curatively for testicular SCSTs, we suggest obtaining any tumor or hormonal markers elevated at diagnosis and computed tomography (CT) of the chest, abdomen, and pelvis every three to six months for the first two years after treatment completion, as metastatic disease occurs most commonly during this time [<a href="#rid3">3,20</a>]. Alternatively, for adults, clinicians may offer a surveillance schedule similar to those with nonseminomatous germ cell tumors of comparable stage and treatment approach. Children with an age-related elevation in alpha-fetoprotein (AFP) at diagnosis should have this marker monitored regularly to ensure a clinically appropriate decline [<a href="#rid20">20</a>]. Patients with juvenile granulosa cell tumor do not require any surveillance imaging or labs [<a href="#rid20">20</a>]. (See  <a class="medical medical_review" href="/z/d/html/2956.html" rel="external">"Posttreatment follow-up for testicular germ cell tumors", section on 'NSGCT'</a>.)</p><p>The duration and frequency of further follow-up is dependent upon the clinician and the patient's histologic diagnosis and clinical disease status. For example, lifelong surveillance is suggested in patients with certain subtypes of SCSTs such as adult type granulosa cell tumors, as these patients can develop metastatic disease many years after diagnosis [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/z/d/html/14236.html" rel="external">"Approach to the care of long-term testicular cancer survivors"</a>.)</p><p>Patients with gynecomastia at diagnosis may be clinically monitored for regression of symptoms, which occurs in approximately 80 percent of patients treated with radical orchiectomy [<a href="#rid3">3</a>]. Persistent or progressive gynecomastia may indicate the presence of a contralateral tumor or recurrent or progressive disease.</p><p>The approach to surveillance of patients with testicular germ cell tumors is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2956.html" rel="external">"Posttreatment follow-up for testicular germ cell tumors"</a>.)</p><p class="headingAnchor" id="H3217920818"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/122274.html" rel="external">"Society guideline links: Testicular cancer"</a>.)</p><p class="headingAnchor" id="H8"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Common histologies</strong> – Testicular sex cord stromal tumors (SCSTs) are rare tumors that arise from the supporting tissues of the testis. Common histologies include Leydig cell tumors, Sertoli cell tumors, and granulosa cell tumors  (<a class="graphic graphic_table graphicRef115023" href="/z/d/graphic/115023.html" rel="external">table 1</a>). (See <a class="local">'Classification and epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – The diagnosis of testicular SCST should be suspected in males presenting with testicular abnormalities and/or specific endocrinologic manifestations (eg, gynecomastia). (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic evaluation</strong> – The initial diagnostic evaluation of a patient with a suspected testicular SCST includes a scrotal ultrasound, tumor markers, and hormonal markers. (See <a class="local">'Diagnostic evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – For all patients presenting with a testicular mass thought to be an SCST, we suggest a radical inguinal orchiectomy rather than a partial orchiectomy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>), in order to establish the histopathologic diagnosis and treat the primary tumor. (See <a class="local">'Diagnosis'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Staging imaging </strong>– For patients with histologically confirmed testicular SCST, we suggest staging for evidence of metastatic disease using computed tomography (CT) of the chest, abdomen, and pelvis  (<a class="graphic graphic_table graphicRef110731" href="/z/d/graphic/110731.html" rel="external">table 2A</a> and <a class="graphic graphic_table graphicRef110732" href="/z/d/graphic/110732.html" rel="external">table 2B</a> and <a class="graphic graphic_table graphicRef128141" href="/z/d/graphic/128141.html" rel="external">table 3</a>). (See <a class="local">'Staging imaging'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Stage I</strong> – For patients with stage I disease treated curatively with orchiectomy and without high-risk pathologic features, we suggest observation rather than further interventions (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>), as these patients have a favorable prognosis. (See <a class="local">'Stage I disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Stage IIA or high-risk features on orchiectomy</strong> – For patients with clinical stage IIA disease or those with two or more high-risk pathologic features on orchiectomy, we suggest early retroperitoneal lymph node dissection (RPLND) rather than observation (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Stage IIA or high-risk features on orchiectomy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Resectable advanced or metastatic disease</strong> – For patients with advanced or metastatic disease who are surgical candidates, we suggest surgical resection of all known sites of disease (including RPLND) rather than other treatment modalities (eg, chemotherapy, radiation) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Surgery to metastatic sites typically occurs after radical orchiectomy has taken place. (See <a class="local">'Advanced or metastatic disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Unresectable metastatic disease</strong> – For patients with unresectable metastatic disease, systemic chemotherapy or radiation therapy (RT) have a limited role due to low response rates. Patients should be evaluated for clinical trials where available. (See <a class="local">'Is there a role for chemotherapy or radiation?'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surveillance</strong> – For patients treated curatively for testicular SCST, we recommend surveillance with tumor and hormonal markers elevated at diagnosis and CT of the chest, abdomen, and pelvis every three to six months for the first two years after treatment completion. The duration and frequency of further follow-up is dependent upon the clinician and the patient's histologic diagnosis and clinical disease status. Alternatively, clinicians may offer a surveillance schedule similar to those with nonseminomatous germ cell tumors of comparable stage and treatment approach. (See <a class="local">'Surveillance'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Dilworth JP, Farrow GM, Oesterling JE. Non-germ cell tumors of testis. Urology 1991; 37:399.</a></li><li><a class="nounderline abstract_t">Mooney KL, Kao CS. A Contemporary Review of Common Adult Non-germ Cell Tumors of the Testis and Paratestis. Surg Pathol Clin 2018; 11:739.</a></li><li><a class="nounderline abstract_t">Acar C, Gurocak S, Sozen S. Current treatment of testicular sex cord-stromal tumors: critical review. Urology 2009; 73:1165.</a></li><li><a class="nounderline abstract_t">Conkey DS, Howard GC, Grigor KM, et al. Testicular sex cord-stromal tumours: the Edinburgh experience 1988-2002, and a review of the literature. Clin Oncol (R Coll Radiol) 2005; 17:322.</a></li><li class="breakAll">Murthy V, Fisher C, Horwich A. Rare tumors of the testis and paratesticular tissues. In: Textbook of Uncommon Cancer, 3rd ed, Raghavan D, Brecher M, Johnson D, et al (Eds), Wiley, 2006. p.66.</li><li><a class="nounderline abstract_t">Schure PJ, van Dalen KC, Ruitenberg HM, van Dalen T. Mesothelioma of the tunica vaginalis testis: a rare malignancy mimicking more common inguino-scrotal masses. J Surg Oncol 2006; 94:162.</a></li><li><a class="nounderline abstract_t">Plas E, Riedl CR, Pflüger H. Malignant mesothelioma of the tunica vaginalis testis: review of the literature and assessment of prognostic parameters. Cancer 1998; 83:2437.</a></li><li><a class="nounderline abstract_t">Moch H, Amin MB, Berney DM, et al. The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. Eur Urol 2022; 82:458.</a></li><li><a class="nounderline abstract_t">Banerji JS, Odem-Davis K, Wolff EM, et al. Patterns of Care and Survival Outcomes for Malignant Sex Cord Stromal Testicular Cancer: Results from the National Cancer Data Base. J Urol 2016; 196:1117.</a></li><li><a class="nounderline abstract_t">Al-Agha OM, Axiotis CA. An in-depth look at Leydig cell tumor of the testis. Arch Pathol Lab Med 2007; 131:311.</a></li><li><a class="nounderline abstract_t">Al-Obaidy KI, Idrees MT. Testicular Tumors: A Contemporary Update on Morphologic, Immunohistochemical and Molecular Features. Adv Anat Pathol 2021; 28:258.</a></li><li class="breakAll">Ulbright TM, Amin MB, Young RH. Ulbright TM, Amin MB, Young RH. In: Atlas of Tumor Pathology, 3rd ed, Rosai J, Sobin LH (Eds), Armed Forces Institute of Pathology, Washington, DC 1999.</li><li><a class="nounderline abstract_t">Ditonno P, Lucarelli G, Battaglia M, et al. Testicular granulosa cell tumor of adult type: a new case and a review of the literature. Urol Oncol 2007; 25:322.</a></li><li><a class="nounderline abstract_t">Al-Bozom IA, El-Faqih SR, Hassan SH, et al. Granulosa cell tumor of the adult type: a case report and review of the literature of a very rare testicular tumor. Arch Pathol Lab Med 2000; 124:1525.</a></li><li><a class="nounderline abstract_t">Arzola J, Hutton RL, Baughman SM, Mora RV. Adult-type testicular granulosa cell tumor: case report and review of the literature. Urology 2006; 68:1121.e13.</a></li><li><a class="nounderline abstract_t">Garrett JE, Cartwright PC, Snow BW, Coffin CM. Cystic testicular lesions in the pediatric population. J Urol 2000; 163:928.</a></li><li><a class="nounderline abstract_t">Algarni AM, Junejo NN, Alkhateeb SS, Al-Hussain TO. Testicular fibroma: A case report and literature review. Urol Ann 2021; 13:308.</a></li><li><a class="nounderline abstract_t">Kim I, Young RH, Scully RE. Leydig cell tumors of the testis. A clinicopathological analysis of 40 cases and review of the literature. Am J Surg Pathol 1985; 9:177.</a></li><li><a class="nounderline abstract_t">Anderson MS, Brogi E, Biller BM. Occult Leydig cell tumor in a patient with gynecomastia. Endocr Pract 2001; 7:267.</a></li><li><a class="nounderline abstract_t">Schultz KA, Schneider DT, Pashankar F, et al. Management of ovarian and testicular sex cord-stromal tumors in children and adolescents. J Pediatr Hematol Oncol 2012; 34 Suppl 2:S55.</a></li><li><a class="nounderline abstract_t">Hassan HC, Cullen IM, Casey RG, Rogers E. Gynaecomastia: an endocrine manifestation of testicular cancer. Andrologia 2008; 40:152.</a></li><li><a class="nounderline abstract_t">Gabrilove JL, Nicolis GL, Mitty HA, Sohval AR. Feminizing interstitial cell tumor of the testis: personal observations and a review of the literature. Cancer 1975; 35:1184.</a></li><li class="breakAll">The Breast: Comprehensive Management of Benign and Malignant Diseases, 5th ed, Bland KI, Copeland EM, Klimberg VS, Gradishar WJ (Eds), Elsevier, Philadelphia 2018.</li><li><a class="nounderline abstract_t">Narula HS, Carlson HE. Gynaecomastia--pathophysiology, diagnosis and treatment. Nat Rev Endocrinol 2014; 10:684.</a></li><li><a class="nounderline abstract_t">Thebaud E, Orbach D, Faure-Conter C, et al. [Specificities of sex-cord stromal tumors in children and adolescents]. Bull Cancer 2015; 102:550.</a></li><li><a class="nounderline abstract_t">Gourlay WA, Johnson HW, Pantzar JT, et al. Gonadal tumors in disorders of sexual differentiation. Urology 1994; 43:537.</a></li><li><a class="nounderline abstract_t">Palmieri V, Al-Mahmeed H, Metrakos P. Bilateral liver metastases from testicular sex cord-stromal tumour. BMJ Case Rep 2019; 12.</a></li><li><a class="nounderline abstract_t">Agrawal CR, Babu Koyyala VP, Talwar V, et al. Malignant Sertoli cell tumor of the testis masquerading as seminoma with bone metastasis. Indian J Pathol Microbiol 2018; 61:596.</a></li><li><a class="nounderline abstract_t">Kumaravelu PG, Vella S, Pontes JE, Heath EI. Malignant undifferentiated sex cord-stromal testis tumor with brain metastasis: case report. Urol Oncol 2008; 26:53.</a></li><li><a class="nounderline abstract_t">Cornejo KM, Young RH. Adult granulosa cell tumors of the testis: a report of 32 cases. Am J Surg Pathol 2014; 38:1242.</a></li><li><a class="nounderline abstract_t">Kao CS, Kum JB, Idrees MT, Ulbright TM. Sclerosing Sertoli cell tumor of the testis: a clinicopathologic study of 20 cases. Am J Surg Pathol 2014; 38:510.</a></li><li><a class="nounderline abstract_t">Gierke CL, King BF, Bostwick DG, et al. Large-cell calcifying Sertoli cell tumor of the testis: appearance at sonography. AJR Am J Roentgenol 1994; 163:373.</a></li><li><a class="nounderline abstract_t">Maizlin ZV, Belenky A, Kunichezky M, et al. Leydig cell tumors of the testis: gray scale and color Doppler sonographic appearance. J Ultrasound Med 2004; 23:959.</a></li><li><a class="nounderline abstract_t">Carvajal-Carmona LG, Alam NA, Pollard PJ, et al. Adult leydig cell tumors of the testis caused by germline fumarate hydratase mutations. J Clin Endocrinol Metab 2006; 91:3071.</a></li><li><a class="nounderline abstract_t">Soria JC, Durdux C, Chrétien Y, et al. Malignant Leydig cell tumor of the testis associated with Klinefelter's syndrome. Anticancer Res 1999; 19:4491.</a></li><li><a class="nounderline abstract_t">Proppe KH, Scully RE. Large-cell calcifying Sertoli cell tumor of the testis. Am J Clin Pathol 1980; 74:607.</a></li><li><a class="nounderline abstract_t">Washecka R, Dresner MI, Honda SA. Testicular tumors in Carney's complex. J Urol 2002; 167:1299.</a></li><li><a class="nounderline abstract_t">Nicolai N, Necchi A, Raggi D, et al. Clinical outcome in testicular sex cord stromal tumors: testis sparing vs. radical orchiectomy and management of advanced disease. Urology 2015; 85:402.</a></li><li><a class="nounderline abstract_t">Laclergerie F, Mouillet G, Frontczak A, et al. Testicle-sparing surgery versus radical orchiectomy in the management of Leydig cell tumors: results from a multicenter study. World J Urol 2018; 36:427.</a></li><li class="breakAll">Pathologic TNM staging of Testis Germ Cell Tumor and Malignant Sex Cord Stromal Tumor (AJCC 8th edition) http://www.pathologyoutlines.com/topic/testisstaging.html?mobile=off (Accessed on April 23, 2020).</li><li><a class="nounderline abstract_t">Hansen PV, Trykker H, Andersen J, Helkjaer PE. Germ cell function and hormonal status in patients with testicular cancer. Cancer 1989; 64:956.</a></li><li><a class="nounderline abstract_t">Featherstone JM, Fernando HS, Theaker JM, et al. Sex cord stromal testicular tumors: a clinical series--uniformly stage I disease. J Urol 2009; 181:2090.</a></li><li><a class="nounderline abstract_t">Silberstein JL, Bazzi WM, Vertosick E, et al. Clinical outcomes of local and metastatic testicular sex cord-stromal tumors. J Urol 2014; 192:415.</a></li><li><a class="nounderline abstract_t">Calaway AC, Tachibana I, Masterson TA, et al. Oncologic Outcomes Following Surgical Management of Clinical Stage II Sex Cord Stromal Tumors. Urology 2019; 127:74.</a></li><li><a class="nounderline abstract_t">Rove KO, Maroni PD, Cost CR, et al. Pathologic Risk Factors for Metastatic Disease in Postpubertal Patients With Clinical Stage I Testicular Stromal Tumors. Urology 2016; 97:138.</a></li><li><a class="nounderline abstract_t">Azizi M, Aydin AM, Cheriyan SK, et al. Therapeutic strategies for uncommon testis cancer histologies: teratoma with malignant transformation and malignant testicular sex cord stromal tumors. Transl Androl Urol 2020; 9:S91.</a></li><li><a class="nounderline abstract_t">Mosharafa AA, Foster RS, Bihrle R, et al. Does retroperitoneal lymph node dissection have a curative role for patients with sex cord-stromal testicular tumors? Cancer 2003; 98:753.</a></li><li><a class="nounderline abstract_t">Bertram KA, Bratloff B, Hodges GF, Davidson H. Treatment of malignant Leydig cell tumor. Cancer 1991; 68:2324.</a></li><li><a class="nounderline abstract_t">Grogg J, Schneider K, Bode PK, et al. Sertoli Cell Tumors of the Testes: Systematic Literature Review and Meta-Analysis of Outcomes in 435 Patients. Oncologist 2020; 25:585.</a></li><li><a class="nounderline abstract_t">Fankhauser CD, Grogg JB, Hayoz S, et al. Risk Factors and Treatment Outcomes of 1,375 Patients with Testicular Leydig Cell Tumors: Analysis of Published Case Series Data. J Urol 2020; 203:949.</a></li><li><a class="nounderline abstract_t">Farkas LM, Székely JG, Pusztai C, Baki M. High frequency of metastatic Leydig cell testicular tumours. Oncology 2000; 59:118.</a></li><li><a class="nounderline abstract_t">Azer PC, Braunstein GD. Malignant Leydig cell tumor: objective tumor response to o,p'-DDD. Cancer 1981; 47:1251.</a></li><li><a class="nounderline abstract_t">van der Hem KG, Boven E, van Hennik MB, Pinedo HM. Malignant Leydig cell tumor of the testis in complete remission on o,p'-dichlorodiphenyl-dichloroethane. J Urol 1992; 148:1256.</a></li><li><a class="nounderline abstract_t">Shang B, Cao C, Jiang W, et al. Promising Immunotherapy in Metastatic Testicular Sex Cord Stromal Tumours After First-Line Chemotherapy. Front Immunol 2021; 12:720359.</a></li><li><a class="nounderline abstract_t">Young RH, Koelliker DD, Scully RE. Sertoli cell tumors of the testis, not otherwise specified: a clinicopathologic analysis of 60 cases. Am J Surg Pathol 1998; 22:709.</a></li><li><a class="nounderline abstract_t">Sawin PD, VanGilder JC. Spinal cord compression from metastatic Leydig's cell tumor of the testis: case report. Neurosurgery 1996; 38:407.</a></li><li><a class="nounderline abstract_t">Samoladas EP, Anbar AS, Lucas JD, et al. Spinal cord compression by a solitary metastasis from a low grade leydig cell tumour: a case report and review of the literature. World J Surg Oncol 2008; 6:75.</a></li><li><a class="nounderline abstract_t">Necchi A, Bratslavsky G, Shapiro O, et al. Genomic Features of Metastatic Testicular Sex Cord Stromal Tumors. Eur Urol Focus 2019; 5:748.</a></li><li><a class="nounderline abstract_t">Grem JL, Robins HI, Wilson KS, et al. Metastatic Leydig cell tumor of the testis. Report of three cases and review of the literature. Cancer 1986; 58:2116.</a></li></ol></div><div id="topicVersionRevision">Topic 2972 Version 27.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2024387" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Non-germ cell tumors of testis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30447839" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : A Contemporary Review of Common Adult Non-germ Cell Tumors of the Testis and Paratestis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19362328" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Current treatment of testicular sex cord-stromal tumors: critical review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16097561" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Testicular sex cord-stromal tumours: the Edinburgh experience 1988-2002, and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16097561" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Testicular sex cord-stromal tumours: the Edinburgh experience 1988-2002, and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16847927" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Mesothelioma of the tunica vaginalis testis: a rare malignancy mimicking more common inguino-scrotal masses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9874447" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Malignant mesothelioma of the tunica vaginalis testis: review of the literature and assessment of prognostic parameters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35853783" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27036305" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Patterns of Care and Survival Outcomes for Malignant Sex Cord Stromal Testicular Cancer: Results from the National Cancer Data Base.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17284120" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : An in-depth look at Leydig cell tumor of the testis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33871428" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Testicular Tumors: A Contemporary Update on Morphologic, Immunohistochemical and Molecular Features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33871428" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Testicular Tumors: A Contemporary Update on Morphologic, Immunohistochemical and Molecular Features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17628299" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Testicular granulosa cell tumor of adult type: a new case and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11035589" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Granulosa cell tumor of the adult type: a case report and review of the literature of a very rare testicular tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17095056" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Adult-type testicular granulosa cell tumor: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10688023" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Cystic testicular lesions in the pediatric population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34421271" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Testicular fibroma: A case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3993830" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Leydig cell tumors of the testis. A clinicopathological analysis of 40 cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11497478" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Occult Leydig cell tumor in a patient with gynecomastia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22525408" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Management of ovarian and testicular sex cord-stromal tumors in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18477201" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Gynaecomastia: an endocrine manifestation of testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1090360" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Feminizing interstitial cell tumor of the testis: personal observations and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1090360" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Feminizing interstitial cell tumor of the testis: personal observations and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25112235" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Gynaecomastia--pathophysiology, diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26028491" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : [Specificities of sex-cord stromal tumors in children and adolescents].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8154078" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Gonadal tumors in disorders of sexual differentiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31122957" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Bilateral liver metastases from testicular sex cord-stromal tumour.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30303161" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Malignant Sertoli cell tumor of the testis masquerading as seminoma with bone metastasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18190831" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Malignant undifferentiated sex cord-stromal testis tumor with brain metastasis: case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24705318" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Adult granulosa cell tumors of the testis: a report of 32 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24552667" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Sclerosing Sertoli cell tumor of the testis: a clinicopathologic study of 20 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8037034" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Large-cell calcifying Sertoli cell tumor of the testis: appearance at sonography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15292565" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Leydig cell tumors of the testis: gray scale and color Doppler sonographic appearance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16757530" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Adult leydig cell tumors of the testis caused by germline fumarate hydratase mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10650798" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Malignant Leydig cell tumor of the testis associated with Klinefelter's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7446466" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Large-cell calcifying Sertoli cell tumor of the testis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11832717" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Testicular tumors in Carney's complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25623702" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Clinical outcome in testicular sex cord stromal tumors: testis sparing vs. radical orchiectomy and management of advanced disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29230496" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Testicle-sparing surgery versus radical orchiectomy in the management of Leydig cell tumors: results from a multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29230496" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Testicle-sparing surgery versus radical orchiectomy in the management of Leydig cell tumors: results from a multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2545331" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Germ cell function and hormonal status in patients with testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19286222" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Sex cord stromal testicular tumors: a clinical series--uniformly stage I disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24518791" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Clinical outcomes of local and metastatic testicular sex cord-stromal tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30807775" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Oncologic Outcomes Following Surgical Management of Clinical Stage II Sex Cord Stromal Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27538802" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Pathologic Risk Factors for Metastatic Disease in Postpubertal Patients With Clinical Stage I Testicular Stromal Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32055490" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Therapeutic strategies for uncommon testis cancer histologies: teratoma with malignant transformation and malignant testicular sex cord stromal tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12910519" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Does retroperitoneal lymph node dissection have a curative role for patients with sex cord-stromal testicular tumors?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1913469" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Treatment of malignant Leydig cell tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32043680" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Sertoli Cell Tumors of the Testes: Systematic Literature Review and Meta-Analysis of Outcomes in 435 Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31845841" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Risk Factors and Treatment Outcomes of 1,375 Patients with Testicular Leydig Cell Tumors: Analysis of Published Case Series Data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10971169" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : High frequency of metastatic Leydig cell testicular tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7226052" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Malignant Leydig cell tumor: objective tumor response to o,p'-DDD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1404649" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Malignant Leydig cell tumor of the testis in complete remission on o,p'-dichlorodiphenyl-dichloroethane.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35082775" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Promising Immunotherapy in Metastatic Testicular Sex Cord Stromal Tumours After First-Line Chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9630178" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Sertoli cell tumors of the testis, not otherwise specified: a clinicopathologic analysis of 60 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8869074" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Spinal cord compression from metastatic Leydig's cell tumor of the testis: case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18616814" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Spinal cord compression by a solitary metastasis from a low grade leydig cell tumour: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31147264" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Genomic Features of Metastatic Testicular Sex Cord Stromal Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3756826" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Metastatic Leydig cell tumor of the testis. Report of three cases and review of the literature.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
